INV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Innventure Inc (INV) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company shows promising growth in bookings and revenue, its financials remain weak with significant net losses and negative gross margins. The technical indicators and options data do not provide a strong bullish signal, and there is no clear momentum in trading sentiment or proprietary trading signals. Given the investor's impatience and unwillingness to wait for optimal entry points, holding off on this investment is recommended until stronger signals or financial improvements are observed.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 54.839, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.12, with resistance at 3.516 and support at 2.725. Overall, the technical indicators suggest a mixed to bearish trend.
Innventure reported over $50 million in bookings for Q1 2026, signaling strong growth potential.
AeroFlexx achieved GMP certification and formed a global partnership with Aveda, enhancing its market position.
Accelsius is expected to be cash flow positive by the end of 2026, supported by a strong sales pipeline.
The company continues to report significant net losses (-$28.33M in Q3
and negative gross margins (-676.59%).
Analyst Nehal Chokshi lowered the price target from $13 to $8, reflecting reduced expectations.
No significant trading trends from hedge funds or insiders, indicating limited confidence from institutional and internal stakeholders.
In Q3 2025, revenue increased by 68.45% YoY to $534,000, showing strong top-line growth. However, the company reported a net loss of $28.33M, an 1181.41% YoY increase in losses. EPS improved to -0.51 (up 920% YoY), but gross margins remain deeply negative at -676.59%. Despite revenue growth, the financials indicate significant operational inefficiencies.
Northland analyst Nehal Chokshi maintains an Outperform rating but lowered the price target from $13 to $8 due to updated share count estimates. This reflects cautious optimism but reduced expectations for the stock.
